Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
Authors
Keywords
Urothelial carcinoma, Bladder cancer, Avelumab, Switch maintenance, Immune checkpoint inhibitor, Immunotherapy
Journal
CANCER TREATMENT REVIEWS
Volume 97, Issue -, Pages 102187
Publisher
Elsevier BV
Online
2021-03-23
DOI
10.1016/j.ctrv.2021.102187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
- (2021) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
- (2020) Hiroto Inoue et al. AURIS NASUS LARYNX
- Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
- (2020) Xin Zhang et al. Frontiers in Immunology
- FINAL OVERALL SURVIVAL ANALYSIS OF THE SOGUG PHASE II MAJA STUDY: MAINTENANCE VINFLUNINE VERSUS BEST SUPPORTIVE CARE AFTER FIRST-LINE CHEMOTHERAPY IN ADVANCED UROTHELIAL CARCINOMA
- (2020) Joaquim Bellmunt Molins et al. Clinical Genitourinary Cancer
- Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
- (2020) Andres Poveda et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
- (2020) Matt D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
- (2020) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- 699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
- (2020) T.B. Powles et al. ANNALS OF ONCOLOGY
- 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
- (2020) P. Grivas et al. ANNALS OF ONCOLOGY
- 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)
- (2020) T.B. Powles et al. ANNALS OF ONCOLOGY
- LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361
- (2020) A. Alva et al. ANNALS OF ONCOLOGY
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
- (2020) Andrea B Apolo et al. Journal for ImmunoTherapy of Cancer
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma
- (2019) Abdalla Aly et al. JOURNAL OF MEDICAL ECONOMICS
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature
- (2019) G. A. Taarnhøj et al. Health and Quality of Life Outcomes
- Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract
- (2019) Cora N. Sternberg et al. EUROPEAN UROLOGY
- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- (2019) Y Fradet et al. ANNALS OF ONCOLOGY
- Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study
- (2019) Kyle Flannery et al. Future Oncology
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Cisplatin contributes to programmed death-ligand 1 (PD-L1) expression in bladder cancer through ERK1/2 - AP-1 signaling pathway
- (2019) Te-Fu Tsai et al. BIOSCIENCE REPORTS
- Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting
- (2019) Jason C. Simeone et al. Cancer Epidemiology
- Changing body weight–based dosing to a flat dose for avelumab in metastatic Merkel cell and advanced urothelial carcinoma
- (2019) Ana M. Novakovic et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
- (2019) Petros Grivas et al. Targeted Oncology
- Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
- (2019) Ludovic Fournel et al. CANCER LETTERS
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- The global burden of urinary bladder cancer: an update
- (2019) Anke Richters et al. WORLD JOURNAL OF UROLOGY
- Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
- (2019) Ali Raza Khaki et al. CANCER
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2018) J B A G Haanen et al. ANNALS OF ONCOLOGY
- Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
- (2018) Karen Kelly et al. CANCER
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function
- (2018) Vadim S. Koshkin et al. Clinical Genitourinary Cancer
- Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
- (2018) Yanan Zheng et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer
- (2018) David J. Vaughn et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015
- (2018) Maxine D. Fisher et al. Clinical Genitourinary Cancer
- Impact of the Number of Cycles of Platinum Based First Line Chemotherapy of Advanced Urothelial Carcinoma
- (2018) Guru P. Sonpavde et al. JOURNAL OF UROLOGY
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
- (2018) Estefanía Paula Juliá et al. Frontiers in Immunology
- FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy
- (2018) Daniel L. Suzman et al. ONCOLOGIST
- Product review: avelumab, an anti-PD-L1 antibody
- (2018) Julie M. Collins et al. Human Vaccines & Immunotherapeutics
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma
- (2017) Laura-Maria Krabbe et al. JOURNAL OF UROLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
- (2017) Jesus García-Donas et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells
- (2016) E. Beyranvand Nejad et al. CANCER RESEARCH
- Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer
- (2016) Emma Eriksson et al. Journal of Translational Medicine
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor
- (2016) A. J. Vandeveer et al. Cancer Immunology Research
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer
- (2015) Cheng Chen et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
- (2014) J. Bellmunt et al. ANNALS OF ONCOLOGY
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
- (2014) A. R. de Biasi et al. CLINICAL CANCER RESEARCH
- Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
- (2014) Alison M. McDonnell et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
- (2013) Petros D. Grivas et al. CANCER
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- (2011) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Interconversion of three measures of performance status: An empirical analysis
- (2010) Clement Ma et al. EUROPEAN JOURNAL OF CANCER
- Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms
- (2010) Zvi G Fridlender et al. MOLECULAR THERAPY
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
- (2009) Tudor Ciuleanu et al. LANCET
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More